NeuroSense Therapeutics Ltd. (NRSN) stock
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
$1.37−0.14 (-9.27%)
Close on Nov 18, 2026Market cap $2.52MP/E –Yield –
NeuroSense Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$11.09M. The highest annual figure on record is -$1.24M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.09M | – |
| FY2024 | Dec 31, 2024 | -$9.90M | – |
| FY2023 | Dec 31, 2023 | -$12.05M | – |
| FY2022 | Dec 31, 2022 | -$10.55M | – |
| FY2021 | Dec 31, 2021 | -$2.99M | – |
| FY2020 | Dec 31, 2020 | -$2.89M | – |
| FY2019 | Dec 31, 2019 | -$1.24M | – |
See a number that looks wrong?